670 related articles for article (PubMed ID: 19861628)
21. Studies on risk of leprosy relapses in China: relapses after treatment with multidrug therapy.
Chen XS; Li WZ; Jiang C; Ye GY
Int J Lepr Other Mycobact Dis; 1999 Dec; 67(4):379-87. PubMed ID: 10700911
[TBL] [Abstract][Full Text] [Related]
22. Twenty five years follow up of MB leprosy patients retreated with a modified MDT regimen after a full course of dapsone mono-therapy.
Jing Z; Zhang R; Zhou D; Chen J
Lepr Rev; 2009 Jun; 80(2):170-6. PubMed ID: 19743621
[TBL] [Abstract][Full Text] [Related]
23. A study on trend of relapse in leprosy and factors influencing relapse.
Ali MK; Thorat DM; Subramanian M; Parthasarathy G; Selvaraj U; Prabhakar V
Indian J Lepr; 2005; 77(2):105-15. PubMed ID: 16044808
[TBL] [Abstract][Full Text] [Related]
24. Four-year follow-up results of a WHO-recommended multiple-drug regimen in paucibacillary leprosy patients in Malawi.
Boerrigter G; Pönnighaus JM; Fine PE; Wilson RJ
Int J Lepr Other Mycobact Dis; 1991 Jun; 59(2):255-61. PubMed ID: 2071983
[TBL] [Abstract][Full Text] [Related]
25. Fixed-duration therapy (FDT) in multibacillary leprosy; efficacy and complications.
Vijayakumaran P; Jesudasan K; Manimozhi N
Int J Lepr Other Mycobact Dis; 1996 Jun; 64(2):123-7. PubMed ID: 8690969
[TBL] [Abstract][Full Text] [Related]
26. Field trial on efficacy of supervised monthly dose of 600 mg rifampin, 400 mg ofloxacin and 100 mg minocycline for the treatment of leprosy; first results.
Mane I; Cartel JL; Grosset JH
Int J Lepr Other Mycobact Dis; 1997 Jun; 65(2):224-9. PubMed ID: 9251595
[TBL] [Abstract][Full Text] [Related]
27. Clinical analysis of multibacillary leprosy patients after 1-year fixed World Health Organization recommended multidrug therapy at Yangon General Hospital, Myanmar.
Kyaw K; Tsoh TM; Swe SY; Nagaoka Y; Takezaki S; Suzuki K; Ishii N
J Dermatol; 2008 May; 35(5):264-9. PubMed ID: 18477225
[TBL] [Abstract][Full Text] [Related]
28. Are viable Mycobacterium leprae present in lepromatous patients after completion of 12 months' and 24 months' multi-drug therapy?
Ebenezer GJ; Daniel S; Norman G; Daniel E; Job CK
Indian J Lepr; 2004; 76(3):199-206. PubMed ID: 15835604
[TBL] [Abstract][Full Text] [Related]
29. Risk of relapse in leprosy after fixed-duration multidrug therapy.
Li HY; Hu LF; Huang WB; Liu GC; Yuan LC; Jin Z; Li X; Li JL; Yang ZM
Int J Lepr Other Mycobact Dis; 1997 Jun; 65(2):238-45. PubMed ID: 9251597
[TBL] [Abstract][Full Text] [Related]
30. Relapses in leprosy patients treated with rifampicin plus dapsone after varying periods of dapsone monotherapy.
Li HY; Ran SP; Weng XM; Li TG; Deng XH; Li FT
Indian J Lepr; 2001; 73(1):1-10. PubMed ID: 11326592
[TBL] [Abstract][Full Text] [Related]
31. Relapses among leprosy patients treated with multidrug therapy: experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia; practical difficulties with diagnosing relapses; operational procedures and criteria for diagnosing relapses.
Becx-Bleumink M
Int J Lepr Other Mycobact Dis; 1992 Sep; 60(3):421-35. PubMed ID: 1474281
[TBL] [Abstract][Full Text] [Related]
32. Drug resistant-Mycobacterium leprae--results of mouse footpad studies from a laboratory in south India.
Ebenezer GJ; Norman G; Joseph GA; Daniel S; Job CK
Indian J Lepr; 2002; 74(4):301-12. PubMed ID: 12624978
[TBL] [Abstract][Full Text] [Related]
33. A study on the impact of FD-MDT on 200 leprosy patients.
Vara N; Marfatiya Y
Indian J Lepr; 2005; 77(3):217-27. PubMed ID: 16353520
[TBL] [Abstract][Full Text] [Related]
34. A study on the effectiveness and safety of the WHO/MDT regimen in the northeast of Thailand; a prospective study, 1984-1996.
Dasananjali K; Schreuder PA; Pirayavaraporn C
Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):28-36. PubMed ID: 9207751
[TBL] [Abstract][Full Text] [Related]
35. Relapses during long-term follow up with drug-susceptible M. leprae among multibacillary leprosy patients treated with multidrug therapy regimens; case reports.
Thomas A; Hari L; Nagarajan M; Prabhakar R
Int J Lepr Other Mycobact Dis; 1995 Sep; 63(3):391-4. PubMed ID: 7594922
[TBL] [Abstract][Full Text] [Related]
36. An 8-12 year follow-up of highly bacillated Indian leprosy patients treated with WHO multi-drug therapy.
Desikan KV; Sundaresh P; Tulasidas I; Rao PV
Lepr Rev; 2008 Sep; 79(3):303-10. PubMed ID: 19009979
[TBL] [Abstract][Full Text] [Related]
37. Fixed-duration multidrug therapy in multibacillary leprosy.
Li HY; Hu LF; Wu PW; Luo JS; Liu XM
Int J Lepr Other Mycobact Dis; 1997 Jun; 65(2):230-7. PubMed ID: 9251596
[TBL] [Abstract][Full Text] [Related]
38. Relapses in paucibacillary leprosy after MDT--a clinical study.
Grugni A; Nadkarni NJ; Kini MS; Mehta VR
Int J Lepr Other Mycobact Dis; 1990 Mar; 58(1):19-24. PubMed ID: 2319185
[TBL] [Abstract][Full Text] [Related]
39. Relapses in multibacillary patients treated with multi-drug therapy until smear negativity: findings after twenty years.
Norman G; Joseph G; Richard J
Int J Lepr Other Mycobact Dis; 2004 Mar; 72(1):1-7. PubMed ID: 15217321
[TBL] [Abstract][Full Text] [Related]
40. OFLOXACIN multicentre trial in MB leprosy FUAM-Manaus and ILSL-Bauru, Brazil.
Cunha Mda G; Virmond M; Schettini AP; Cruz RC; Ura S; Ghuidella C; Viana Fdos R; Avelleira JC; Campos AA; Filho B
Lepr Rev; 2012 Sep; 83(3):261-8. PubMed ID: 23356027
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]